foscarnet has been researched along with Cytomegaloviral Retinitis in 191 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 9.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "Two hundred thirty-four patients with the acquired immunodeficiency syndrome and previously untreated cytomegalovirus retinitis at 11 university centers were randomly assigned to receive intravenously either foscarnet (n = 107) or ganciclovir (n = 127)." | 9.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir." | 9.08 | Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. ( Jabs, DA, 1996) |
| "The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy." | 9.08 | Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ( Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995) |
| " The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial is a multicenter, randomized, controlled, unmasked, clinical trial that compared ganciclovir and foscarnet as treatments for CMV retinitis in patients with AIDS." | 9.07 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1994) |
| "The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed." | 9.07 | Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. ( Causey, D; Davis, R; Feinberg, J; Heinemann, MH; Jacobson, MA; Kuppermann, BD; Lizak, P; O'Donnell, JJ; Polsky, B; Tong, W, 1994) |
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 9.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 9.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 7.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "The purpose of this report was to develop solvent-free biodegradable scleral plugs for simultaneous ganciclovir and foscarnet delivery for cytomegalovirus retinitis treatment." | 7.76 | Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis. ( Chiou, SH; Liu, SJ; Peng, YJ; Wen, CW, 2010) |
| "To describe the chronic use of high doses of intravitreal ganciclovir, in combination with foscarnet, for the treatment of cytomegalovirus retinitis." | 7.71 | High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. ( Chan, CC; Robinson, MR; Roy, CE; Velez, G; Whitcup, SM, 2001) |
| "We report three pediatric patients with ganciclovir-resistant cytomegalovirus (CMV) retinitis who were successfully treated with foscarnet." | 7.71 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. ( Amo, K; Aono, T; Hara, J; Kim, JY; Matsuda, Y; Miyagawa, H; Ohta, H; Okada, S; Sashihara, J; Sawada, A; Tanaka-Taya, K; Tano, Y; Tokimasa, S; Yamamoto, S; Yamanishi, K, 2001) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 7.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| "Viral resistance to foscarnet or ganciclovir may explain refractory cytomegalovirus retinitis in some patients." | 7.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 7.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 7.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 7.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 7.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment." | 7.69 | Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ( Arevalo, JF; Bergeron-Lynn, G; Capparelli, EV; Connor, JD; Freeman, WR; Gambertoglio, J; Garcia, RF; Gonzalez, C; Kirsch, LS; Quiceno, JI, 1995) |
| "We report on a 28-year-old AIDS patient who developed a rapidly progressive glomerulonephritis while being treated with foscarnet for cytomegalovirus retinitis." | 7.69 | Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. ( Cahen, R; Cotte, L; Dijoud, F; François, B; Patricot, LM; Trepo, C; Trolliet, P, 1995) |
| "Foscarnet is a pyrophosphate analogue that possesses substantial activity against human cytomegalovirus (HCMV) in patients with CMV retinitis." | 7.69 | In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet. ( Cinatl, J; Doerr, HW; Gümbel, HO; Ohrloff, C; Rabenau, H; Rückert, DG, 1994) |
| "To assess the clinical response and patient tolerance to daily infusions of both ganciclovir sodium and foscarnet sodium for the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome." | 7.68 | Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. ( Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993) |
| " In both regimens the elimination half-life of foscarnet was 2-3 h." | 6.68 | Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. ( Carosi, G; Castelli, F; Hedman, A; Suter, F; Tomasoni, L; Trespi, G; Zeroli, C, 1997) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 6.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| "Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned." | 6.68 | Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group ( , 1997) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 5.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 5.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| "Cytomegalovirus retinitis is the leading cause of blindness in adults and children with acquired immunodeficiency syndrome (AIDS)." | 5.29 | Combined ganciclovir and foscarnet in pediatric cytomegalovirus retinitis. ( Epps, CH; Rana, SN; Sanders, RJ; Sastry, SM; Walton, RC, 1996) |
| "The clinical significance of cytomegalovirus (CMV) foscarnet resistance was studied in patients with acquired immunodeficiency syndrome and CMV retinitis." | 5.10 | Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. ( Chou, S; Crumpacker, C; Forman, MS; Jabs, DA; Lurain, NS; Martin, BK; Weinberg, A, 2003) |
| "Two hundred thirty-four patients with the acquired immunodeficiency syndrome and previously untreated cytomegalovirus retinitis at 11 university centers were randomly assigned to receive intravenously either foscarnet (n = 107) or ganciclovir (n = 127)." | 5.08 | Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. ( , 1995) |
| "The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir." | 5.08 | Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. ( Jabs, DA, 1996) |
| "Twenty-six subjects enrolled in a randomized trial that compared foscarnet and ganciclovir for the treatment of cytomegalovirus retinitis." | 5.08 | Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group. ( Coleson, LC; Holbrook, J; Jabs, DA; Wu, AW, 1996) |
| "The use of foscarnet and ganciclovir as a combination treatment for cytomegalovirus retinitis is increasing because of limitations associated with single agent therapy." | 5.08 | Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis. ( Aweeka, FT; Emrick, L; Gambertoglio, JG; Jacobson, MA; Jayewardene, A; Kramer, F; Lizak, P; Polsky, B; Tong, W; van der Horst, C, 1995) |
| "The aim of this study was to investigate peripheral blood polymorphonuclear leukocytes and, whenever possible, aqueous humor from 65 AIDS patients with ophthalmoscopically diagnosed human cytomegalovirus (HCMV) retinitis to determine (i) whether patients consistently carry viral DNA and (ii) to what extent foscarnet induction treatment decreases viral DNA levels." | 5.07 | Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group. ( Baldanti, F; Furione, M; Gerna, G; Percivalle, E; Revello, MG; Sarasini, A; Zella, D; Zipeto, D, 1994) |
| "The efficacy and tolerance of high dose intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS was studied." | 5.07 | High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. ( Cano, J; Chipont, E; Diaz-Llopis, M; España, E; Menezo, JL; Muñoz, G; Navea, A; Romero, FJ, 1994) |
| "The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed." | 5.07 | Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. ( Causey, D; Davis, R; Feinberg, J; Heinemann, MH; Jacobson, MA; Kuppermann, BD; Lizak, P; O'Donnell, JJ; Polsky, B; Tong, W, 1994) |
| " The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial is a multicenter, randomized, controlled, unmasked, clinical trial that compared ganciclovir and foscarnet as treatments for CMV retinitis in patients with AIDS." | 5.07 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1994) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 3.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "The purpose of this report was to develop solvent-free biodegradable scleral plugs for simultaneous ganciclovir and foscarnet delivery for cytomegalovirus retinitis treatment." | 3.76 | Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis. ( Chiou, SH; Liu, SJ; Peng, YJ; Wen, CW, 2010) |
| "We report three pediatric patients with ganciclovir-resistant cytomegalovirus (CMV) retinitis who were successfully treated with foscarnet." | 3.71 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA. ( Amo, K; Aono, T; Hara, J; Kim, JY; Matsuda, Y; Miyagawa, H; Ohta, H; Okada, S; Sashihara, J; Sawada, A; Tanaka-Taya, K; Tano, Y; Tokimasa, S; Yamamoto, S; Yamanishi, K, 2001) |
| "A 7-year-old HIV-infected male with frosted branch angiitis was refractory to induction doses of intravenous ganciclovir and foscarnet over a 2-month period." | 3.71 | Frosted branch angiitis in a child with HIV infection. ( Fine, HF; Murante, BL; Nussenblatt, RB; Robinson, MR; Smith, JA, 2001) |
| "To describe the chronic use of high doses of intravitreal ganciclovir, in combination with foscarnet, for the treatment of cytomegalovirus retinitis." | 3.71 | High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis. ( Chan, CC; Robinson, MR; Roy, CE; Velez, G; Whitcup, SM, 2001) |
| "Three acquired immune deficiency syndrome patients given foscarnet to treat cytomegalovirus retinitis developed renal failure with crystal deposits within the renal glomeruli." | 3.70 | Identification of crystals in kidneys of AIDS patients treated with foscarnet. ( Beaufils, H; Daudon, M; Jouanneau, C; Katlama, C; Lacour, B; Maurice-Estepa, L; Sazdovitch, V, 1998) |
| "To determine intraocular toxicity and efficacy of the lipid prodrug of foscarnet, 1-O-octadecyl-sn-glycerol-3-phosphonoformate (ODG-PFA), as a long-acting, nontoxic intravitreous injectable drug delivery system for cytomegalovirus (CMV) retinitis." | 3.70 | Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. ( Avila, CP; Bergeron-Lynn, G; Cheng, L; Freeman, WR; Gardner, MF; Hostetler, KY; Keefe, KS; Wiley, CA, 1999) |
| "Three human immunodeficiency virus-infected subjects with progressive cytomegalovirus (CMV) retinitis despite prolonged antiviral therapy had buffy coat CMV isolates that were resistant to both ganciclovir and foscarnet." | 3.70 | Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. ( Chou, S; Drew, WL; Gordon, SM; LaVoy, AG; Marousek, G; Miner, RC; Parenti, DM; Ross, JG, 1998) |
| "A patient with AIDS and cytomegalovirus (CMV) retinitis received ganciclovir and foscarnet for 20 and 5 months, respectively, with evidence of periodic disease progression." | 3.70 | A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. ( Chou, S; Drew, WL; Miner, RC, 2000) |
| "This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment." | 3.69 | Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ( Arevalo, JF; Bergeron-Lynn, G; Capparelli, EV; Connor, JD; Freeman, WR; Gambertoglio, J; Garcia, RF; Gonzalez, C; Kirsch, LS; Quiceno, JI, 1995) |
| "These results suggest that while ganciclovir therapy may clinically stabilize CMV retinitis in patients with AIDS, it does not appear to prevent the development of, or be effective in the treatment of, CMV encephalitis." | 3.69 | The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. ( Berman, SM; Kim, RC, 1994) |
| "To determine the efficacy of combined ganciclovir and foscarnet intravitreal injections in controlling clinically resistant cytomegalovirus retinitis in a 37-year-old man with the acquired immunodeficiency syndrome who refused systemic therapy." | 3.69 | Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. ( Desatnik, HR; Foster, RE; Lowder, CY, 1996) |
| "To determine the prevalence of cytomegalovirus (CMV) isolates resistant to ganciclovir sodium or foscarnet sodium at the time of diagnosis of CMV retinitis, prior to the initiation of therapy." | 3.69 | Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group. ( Bressler, N; Charache, P; Dunn, JP; Enger, C; Forman, M; Jabs, DA, 1996) |
| "Foscarnet is a pyrophosphate analogue that possesses substantial activity against human cytomegalovirus (HCMV) in patients with CMV retinitis." | 3.69 | In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet. ( Cinatl, J; Doerr, HW; Gümbel, HO; Ohrloff, C; Rabenau, H; Rückert, DG, 1994) |
| " We attempted to detect cytomegalovirus DNA in 19 vitreous samples from patients with the acquired immunodeficiency syndrome (AIDS) who had untreated cytomegalovirus retinitis and in 40 vitreous samples from patients with AIDS who had been treated with systemic ganciclovir or foscarnet, or both." | 3.69 | A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis. ( Ai, E; Irvine, AR; Kuppermann, BD; Luckie, AP; Margolis, TP; McCann, JD; Schwartz, DM; Wong, MG, 1995) |
| "We treated seven patients (nine eyes) who had cytomegalovirus retinitis with daily intravenous ganciclovir plus foscarnet." | 3.69 | Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis. ( Murphy, R; Naughton, K; Weinberg, DV, 1994) |
| " Administration of foscarnet during two years, recommended as suppressive therapy for a previous cytomegalovirus retinitis, might have caused a sustained reduction in plasma HIV-RNA, contributing to her long-term survival." | 3.69 | [Long term survival in an HIV-immunosuppressed patient treated with foscarnet]. ( Bravo, R; González-Lahoz, J; Mas, A; Moreno, V; Soriano, V, 1996) |
| "We report on a 28-year-old AIDS patient who developed a rapidly progressive glomerulonephritis while being treated with foscarnet for cytomegalovirus retinitis." | 3.69 | Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. ( Cahen, R; Cotte, L; Dijoud, F; François, B; Patricot, LM; Trepo, C; Trolliet, P, 1995) |
| "Viral resistance to foscarnet or ganciclovir may explain refractory cytomegalovirus retinitis in some patients." | 3.69 | Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. ( Apuzzo, L; Charache, P; Dunn, JP; Forman, MS; Jabs, DA; MacCumber, MW, 1995) |
| "Advances in ganciclovir and foscarnet therapies for treating cytomegalovirus retinitis, including ocular implants and injections, alternating use of foscarnet and ganciclovir, oral ganciclovir use, cidofovir treatment, and injecting either ganciclovir or foscarnet directly into affected eyes, are discussed." | 3.69 | Advances in treatment for cytomegalovirus retinitis. ( Bowers, M, 1995) |
| "Cytomegalovirus (CMV) retinitis, a sight-threatening infection common in AIDS patients, can be treated systemically with intravenous ganciclovir, intravenous foscarnet, or oral ganciclovir." | 3.69 | Intraocular therapy for cytomegalovirus retinitis. ( Palestine, AG, 1996) |
| "Foscavir (foscarnet sodium) has been approved by the Food and Drug Administration (FDA) for use in combination with Cytovene (intravenous ganciclovir) for the treatment of recurrent AIDS-related cytomegalovirus retinitis that has been treated previously with either drug alone." | 3.69 | Foscavir receives new indication. ( , 1997) |
| "To assess the clinical response and patient tolerance to daily infusions of both ganciclovir sodium and foscarnet sodium for the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome." | 3.68 | Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. ( Flores-Aguilar, M; Freeman, WR; Kuppermann, BD; Quiceno, JI; Rickman, LS, 1993) |
| "ACTG 266 was designed as a randomized study to evaluate two doses of the human monoclonal antibody directed against CMV gH (MSL-109) versus placebo, each in combination with standard antiviral therapy for the treatment of newly diagnosed Cytomegalovirus (CMV) retinitis in AIDS patients." | 2.71 | A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re ( Alston, B; Asmuth, DM; Aweeka, F; Borucki, MJ; Caliendo, A; Gnann, J; Hirsch, MS; Hubbard, L; Nadler, PI; Nevin, TT; Nokta, M; Owens, S; Pollard, RB; Sattler, F; Spritzler, J; Waterman, K, 2004) |
| "Patients were randomized to one of three therapeutic regimens: induction with foscarnet sodium at 90 mg/kg intravenously every 12 hours for 2 weeks, followed by maintenance at a dosage of 120 mg/kg per day (foscarnet group); induction with ganciclovir sodium at 5 mg/kg intravenously every 12 hours for 2 weeks followed by maintenance at 10 mg/kg per day (ganciclovir group); or continuation of previous maintenance therapy plus induction with the other drug (either ganciclovir or foscarnet) for 2 weeks followed by maintenance therapy with both drugs, ganciclovir sodium at 5 mg/kg per day and foscarnet sodium at 90 mg/kg per day (combination therapy group)." | 2.68 | Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration ( , 1996) |
| " In both regimens the elimination half-life of foscarnet was 2-3 h." | 2.68 | Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis. ( Carosi, G; Castelli, F; Hedman, A; Suter, F; Tomasoni, L; Trespi, G; Zeroli, C, 1997) |
| " However, patients with positive baseline CMV blood cultures had a significantly more shallow dose-response curve." | 2.68 | Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. ( Aweeka, F; Drusano, GL; Eaton, C; Gambertoglio, J; Jacobson, M; Lane, HC; Martin-Munley, S; Polis, M, 1996) |
| "Retinal detachment was not associated with the type of anticytomegalovirus therapy (intravenous foscarnet or ganciclovir) to which the patient was assigned." | 2.68 | Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group ( , 1997) |
| "However, it may develop in patients with acute lymphoblastic leukemia (ALL) who have not undergone hematopoietic cell transplantation." | 2.53 | Cytomegalovirus Retinitis in Three Pediatric Cases with Acute Lymphoblastic Leukemia: Case Series and Review of the Literature. ( Akkoç, G; Atıcı, S; Bakır, M; Çeliker, H; Demir, SÖ; Kadayifci, EK; Karaaslan, A; Kazokoğlu, H; Koç, A; Şenay, E; Soysal, A; Yakut, N, 2016) |
| " Valganciclovir, a prodrug of ganciclovir, offers excellent oral bioavailability and is the closest to approval of all the new anti-CMV drugs." | 2.41 | Therapeutic developments in cytomegalovirus retinitis. ( Hoffman, VF; Skiest, DJ, 2000) |
| "CMV-related retinal detachment is treated surgically." | 2.40 | Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. ( Au Eong, KG; Beatty, S; Charles, SJ, 1999) |
| " Other new methods involve liposomal systems to increase drug contact time, use of longer-acting drugs with less-frequent dosing requirements, and methods to improve quality of life by avoiding intravenous drug delivery." | 2.40 | Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities. ( Bright, DC, 1997) |
| "The median number of recurrences up to the observation of foveal-sparing retinitis was two (range one to eight), and five patients had active CMV retinitis despite treatment for at least two continuous months." | 2.39 | A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome. ( Ai, E; Luckie, AP, 1996) |
| "Foscarnet sodium is an antiviral drug for the treatment of CMV retinitis, currently in the form of twice-weekly intravitreal injection." | 1.46 | Foscarnet calcium microcrystals as the intravitreal drug depot. ( Cao, Q; Huang, Y; Sun, Y; Tao, Y, 2017) |
| "Bilateral recurrence of CMV retinitis occurred on day 89 of life, requiring a second course of intravitreal foscarnet injections and intravenous ganciclovir." | 1.40 | Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant. ( Baumal, CR; Tawse, KL, 2014) |
| "The incidence of cytomegalovirus retinitis has decreased significantly since the advent of antiretroviral therapy." | 1.40 | Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy. ( Acheson, RW; Adler, H; Brannigan, ET; De Gascun, CF; Duffy, M; Keegan, DJ; Lambert, JS; McSweeney, F, 2014) |
| "Cytomegalovirus retinitis is an opportunistic infection found in AIDS patients as well as in bone marrow and solid organ transplant recipients being treated with systemic immunosuppressive drugs." | 1.39 | A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma. ( Brichová, M; Dvořák, J; Heissigerová, J; Kalvodová, B; Ríhová, E; Svozílková, P, 2013) |
| "Retinal detachment is the main complication." | 1.32 | [Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients]. ( Laroche, L; Larricart, P; Metge, F; Monin, C; Morel, C; Roman, S; Scheer, S, 2004) |
| "An exacerbation of the myelitis, retinitis, encephalitis and colitis was observed and a cytomegalovirus infection diagnosed." | 1.31 | CMV complications in common variable immunodeficiency. ( Schmidt, RE; Werwitzke, S; Witte, T, 2000) |
| "In one eye, the cystoid macular edema was worsened by formation of a dense juxtafoveal epiretinal membrane." | 1.30 | Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Cunningham, ET; Jones, MR; Schwartz, D; Silverstein, BE; Smith, JH; Sykes, SO, 1998) |
| "A mild recurrence developed in one eye when ganciclovir and foscarnet were both tapered to a single daily dose." | 1.30 | The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy. ( Ciulla, TA; Duker, JS; Morley, MG; Rutledge, BK, 1998) |
| "Retinal detachment was seen in 14 patients (relative frequency, 19." | 1.29 | Retinal detachment in patients with acquired immunodeficiency syndrome. ( Bogner, JR; Geier, SA; Goebel, FD; Klauss, V; Sadri, I; Schmidt-Kittler, H, 1994) |
| "CMV viremia was present in 4 patients." | 1.29 | Cytomegalovirus ventriculoencephalitis in AIDS patients. ( Fernandez-Viladrich, P; Ferrer, I; Gudiol, F; Perez, JL; Podzamczer, D; Reñe, R; Salazar, A; Santin, M, 1995) |
| "Sera obtained from AIDS patients with cytomegalovirus (CMV) retinitis before and after treatment with foscarnet, AIDS patients with human immunodeficiency virus (HIV) retinopathy, AIDS patients without retinal disease, and normal healthy controls with and without positive CMV serologies were assayed for the presence of antibodies against the 200-kDa outer, 160-kDa middle, and 68-kDa core subunits of the neurofilament triplet." | 1.29 | Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis. ( Cunningham-Rundles, S; Heinemann, MH; Klein, RF; Polsky, B; Rosberger, DF; Tshering, SL, 1994) |
| "Approximately one-third of all AIDS patients develop cytomegalovirus (CMV) retinitis." | 1.29 | Detecting CMV retinitis: know what to look for. Treatment is effective but not pleasant. ( , 1996) |
| " The dosing regimen for induction with the combined therapy was foscarnet (60 mg/kg every 8 hours) and ganciclovir (5 mg/kg daily for 3 weeks)." | 1.29 | Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis. ( Lewis, LL; Mueller, BU; Nussenblatt, RB; Pizzo, PA; Walton, RC; Whitcup, SM, 1995) |
| "In persons with AIDS (PWAs), cytomegalovirus (CMV) infection can cause a broad spectrum of clinical manifestations." | 1.29 | Spectrum and treatment of cytomegalovirus disease in persons with AIDS. ( Spector, SA, 1996) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 1.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| "Cytomegalovirus retinitis is the leading cause of blindness in adults and children with acquired immunodeficiency syndrome (AIDS)." | 1.29 | Combined ganciclovir and foscarnet in pediatric cytomegalovirus retinitis. ( Epps, CH; Rana, SN; Sanders, RJ; Sastry, SM; Walton, RC, 1996) |
| "A patient with Hodgkin's disease presented with an atypical retinitis, vasculitis, and a serous macular detachment." | 1.29 | Cytomegalovirus retinitis associated with Hodgkin's disease. ( Jaffe, GJ; Nasir, MA, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 142 (74.35) | 18.2507 |
| 2000's | 27 (14.14) | 29.6817 |
| 2010's | 20 (10.47) | 24.3611 |
| 2020's | 2 (1.05) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, HJ | 1 |
| Woo, SJ | 1 |
| Hafidi, M | 1 |
| Janin-Manificat, H | 1 |
| Denis, P | 1 |
| Charleux, B | 1 |
| Rabilloud, M | 1 |
| Boibieux, A | 1 |
| Burillon, C | 1 |
| Kodjikian, L | 1 |
| Frobert, E | 1 |
| Fu, L | 1 |
| Santhanakrishnan, K | 1 |
| Al-Aloul, M | 1 |
| Jones, NP | 1 |
| Steeples, LR | 1 |
| Sun, Y | 1 |
| Tao, Y | 1 |
| Cao, Q | 1 |
| Huang, Y | 1 |
| Rothman, AL | 1 |
| Walter, SD | 1 |
| Gupta, S | 1 |
| Vemulakonda, GA | 1 |
| Suhler, EB | 1 |
| Yeh, S | 3 |
| Albini, TA | 2 |
| Mandelcorn, E | 1 |
| Flaxel, CJ | 2 |
| Schneider, EW | 1 |
| Elner, SG | 1 |
| van Kuijk, FJ | 1 |
| Goldberg, N | 1 |
| Lieberman, RM | 2 |
| Eliott, D | 1 |
| Johnson, MW | 1 |
| Adler, H | 1 |
| De Gascun, CF | 1 |
| McSweeney, F | 1 |
| Acheson, RW | 1 |
| Brannigan, ET | 1 |
| Duffy, M | 1 |
| Keegan, DJ | 1 |
| Lambert, JS | 1 |
| Tawse, KL | 1 |
| Baumal, CR | 1 |
| Vishnevskia-Dai, V | 1 |
| Shapira, Y | 1 |
| Rahav, G | 1 |
| Shimoni, A | 1 |
| Somech, R | 1 |
| Moisseiev, J | 1 |
| Churgin, D | 1 |
| Relhan, N | 1 |
| Davis, JL | 1 |
| Timperley, A | 1 |
| Taha, H | 1 |
| Das, S | 1 |
| Demir, SÖ | 1 |
| Çeliker, H | 1 |
| Karaaslan, A | 1 |
| Kadayifci, EK | 1 |
| Akkoç, G | 1 |
| Atıcı, S | 1 |
| Yakut, N | 1 |
| Şenay, E | 1 |
| Kazokoğlu, H | 1 |
| Koç, A | 1 |
| Bakır, M | 1 |
| Soysal, A | 1 |
| Boss, JD | 1 |
| Rosenberg, K | 1 |
| Shah, R | 1 |
| Oshima, K | 1 |
| Kanda, Y | 1 |
| Kako, S | 1 |
| Asano-Mori, Y | 1 |
| Watanabe, T | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Shiraki, K | 1 |
| Kurokawa, M | 1 |
| Rothova, A | 1 |
| de Weerdt, O | 1 |
| Jabs, DA | 12 |
| Martin, BK | 3 |
| Forman, MS | 3 |
| Peng, YJ | 1 |
| Wen, CW | 1 |
| Chiou, SH | 1 |
| Liu, SJ | 1 |
| Forooghian, F | 2 |
| Faia, LJ | 2 |
| Weichel, ED | 2 |
| Wong, WT | 1 |
| Sen, HN | 2 |
| Chan-Kai, BT | 1 |
| Witherspoon, SR | 1 |
| Lauer, AK | 2 |
| Chew, EY | 1 |
| Nussenblatt, RB | 4 |
| Fahle, G | 1 |
| Stout, JT | 1 |
| Moss, HB | 1 |
| Chavala, S | 1 |
| Say, E | 1 |
| Miller, MB | 1 |
| Kobayashi, R | 1 |
| Takanashi, K | 1 |
| Suzuki, D | 1 |
| Nasu, T | 1 |
| Uetake, K | 1 |
| Matsumoto, Y | 1 |
| Martínez-Castillo, S | 1 |
| Marín-Lambíes, C | 1 |
| Gallego-Pinazo, R | 1 |
| Arévalo, JF | 2 |
| Díaz-Llopis, M | 2 |
| Svozílková, P | 1 |
| Heissigerová, J | 1 |
| Brichová, M | 1 |
| Kalvodová, B | 1 |
| Dvořák, J | 1 |
| Ríhová, E | 1 |
| Larsson, K | 1 |
| Lönnqvist, B | 1 |
| Ringdén, O | 1 |
| Hedquist, B | 1 |
| Ljungman, P | 1 |
| Holbrook, JT | 2 |
| Weinberg, DV | 2 |
| Lewis, RA | 1 |
| Davis, MD | 2 |
| Friedberg, D | 1 |
| Weinberg, A | 1 |
| Chou, S | 3 |
| Lurain, NS | 1 |
| Crumpacker, C | 1 |
| Rapp, P | 1 |
| Pilon, F | 1 |
| Chiambaretta, F | 1 |
| Ménérath, JM | 1 |
| Jacomet, C | 1 |
| Morel, C | 1 |
| Metge, F | 1 |
| Roman, S | 1 |
| Scheer, S | 1 |
| Larricart, P | 1 |
| Monin, C | 1 |
| Laroche, L | 1 |
| Borucki, MJ | 1 |
| Spritzler, J | 1 |
| Asmuth, DM | 1 |
| Gnann, J | 1 |
| Hirsch, MS | 1 |
| Nokta, M | 1 |
| Aweeka, F | 2 |
| Nadler, PI | 1 |
| Sattler, F | 1 |
| Alston, B | 1 |
| Nevin, TT | 1 |
| Owens, S | 2 |
| Waterman, K | 1 |
| Hubbard, L | 2 |
| Caliendo, A | 1 |
| Pollard, RB | 2 |
| Demols, P | 1 |
| Claes, CA | 1 |
| Farber, CM | 1 |
| Rasquin, F | 1 |
| Nakamoto, BK | 1 |
| Dorotheo, EU | 1 |
| Biousse, V | 1 |
| Tang, RA | 1 |
| Schiffman, JS | 1 |
| Newman, NJ | 1 |
| Ausayakhun, S | 1 |
| Watananikorn, S | 1 |
| Ngamtiphakorn, S | 1 |
| Prasitsilp, J | 1 |
| Ufret-Vincenty, RL | 1 |
| Singh, RP | 1 |
| Lowder, CY | 3 |
| Kaiser, PK | 1 |
| Eid, AJ | 1 |
| Bakri, SJ | 1 |
| Kijpittayarit, S | 1 |
| Razonable, RR | 1 |
| Luckie, AP | 3 |
| Fitzgerald, E | 1 |
| Goldman, HM | 1 |
| Miller, WG | 1 |
| Purcell, SM | 1 |
| Gonzalez, C | 1 |
| Capparelli, EV | 1 |
| Kirsch, LS | 1 |
| Garcia, RF | 1 |
| Quiceno, JI | 3 |
| Connor, JD | 1 |
| Gambertoglio, J | 2 |
| Bergeron-Lynn, G | 2 |
| Freeman, WR | 7 |
| Trolliet, P | 1 |
| Dijoud, F | 1 |
| Cotte, L | 1 |
| Cahen, R | 1 |
| François, B | 1 |
| Trepo, C | 1 |
| Patricot, LM | 1 |
| McCann, JD | 1 |
| Margolis, TP | 1 |
| Wong, MG | 1 |
| Kuppermann, BD | 4 |
| Schwartz, DM | 1 |
| Irvine, AR | 2 |
| Ai, E | 2 |
| Holida, MD | 1 |
| Trigg, ME | 1 |
| Rumelhart, SL | 1 |
| Lee, NF | 1 |
| Kook, H | 1 |
| Peters, C | 1 |
| Salazar, A | 1 |
| Podzamczer, D | 1 |
| Reñe, R | 1 |
| Santin, M | 1 |
| Perez, JL | 1 |
| Ferrer, I | 1 |
| Fernandez-Viladrich, P | 1 |
| Gudiol, F | 1 |
| Engstrom, RE | 1 |
| Holland, GN | 3 |
| Thimons, JJ | 1 |
| Aweeka, FT | 1 |
| Gambertoglio, JG | 1 |
| Kramer, F | 1 |
| van der Horst, C | 1 |
| Polsky, B | 4 |
| Jayewardene, A | 1 |
| Lizak, P | 2 |
| Emrick, L | 1 |
| Tong, W | 2 |
| Jacobson, MA | 8 |
| Polis, MA | 1 |
| Masur, H | 1 |
| Dunn, JP | 4 |
| MacCumber, MW | 1 |
| Charache, P | 2 |
| Apuzzo, L | 1 |
| Levinson, RD | 1 |
| Balfour, HH | 1 |
| Colucciello, M | 1 |
| Moyle, G | 1 |
| Gazzard, BG | 2 |
| Albrecht, H | 1 |
| Stellbrink, HJ | 1 |
| Brewster, D | 1 |
| Greten, H | 1 |
| Wulfsohn, M | 1 |
| Feinberg, JE | 1 |
| Davis, R | 2 |
| Power, M | 1 |
| Causey, D | 2 |
| Heath-Chiozzi, ME | 1 |
| Murphy, RL | 1 |
| Cheung, TW | 1 |
| Nagata, Y | 1 |
| Fujino, Y | 1 |
| Ono, A | 1 |
| Mochizuki, M | 1 |
| Mouri, H | 1 |
| Oka, S | 1 |
| Kimura, S | 1 |
| Shimada, K | 1 |
| O'Donnell, JJ | 1 |
| Heinemann, MH | 3 |
| Feinberg, J | 1 |
| Orellana, J | 1 |
| Melton, RC | 1 |
| España, E | 1 |
| Muñoz, G | 1 |
| Navea, A | 1 |
| Chipont, E | 1 |
| Cano, J | 1 |
| Menezo, JL | 1 |
| Romero, FJ | 1 |
| Gerna, G | 2 |
| Baldanti, F | 1 |
| Sarasini, A | 1 |
| Furione, M | 1 |
| Percivalle, E | 1 |
| Revello, MG | 1 |
| Zipeto, D | 1 |
| Zella, D | 1 |
| Gümbel, HO | 1 |
| Rückert, DG | 1 |
| Cinatl, J | 2 |
| Rabenau, H | 1 |
| Doerr, HW | 1 |
| Ohrloff, C | 1 |
| Geier, SA | 2 |
| Klauss, V | 1 |
| Bogner, JR | 2 |
| Schmidt-Kittler, H | 1 |
| Sadri, I | 2 |
| Goebel, FD | 2 |
| Berman, SM | 1 |
| Kim, RC | 1 |
| Murphy, R | 1 |
| Naughton, K | 1 |
| Flores-Aguilar, M | 2 |
| Rickman, LS | 1 |
| Leport, C | 1 |
| Puget, S | 1 |
| Pepin, JM | 1 |
| Levy, S | 1 |
| Perronne, C | 1 |
| Brun-Vezinet, F | 1 |
| Vildé, JL | 1 |
| Ricart Olmos, C | 1 |
| López Aldeguer, J | 1 |
| Marino Blanes Juliá, F | 1 |
| Sinelni, E | 1 |
| Roarty, JD | 1 |
| Fisher, EJ | 1 |
| Nussbaum, JJ | 1 |
| Friedberg, DN | 3 |
| Berry, C | 1 |
| Behette, M | 1 |
| Fullerton, SC | 1 |
| Munguia, D | 1 |
| Spaide, RF | 1 |
| Young, LH | 2 |
| Giezendanner, S | 1 |
| Wirth, HP | 1 |
| Zala, G | 1 |
| Weber, R | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Rosberger, DF | 1 |
| Tshering, SL | 1 |
| Klein, RF | 1 |
| Cunningham-Rundles, S | 1 |
| Jayaweera, D | 1 |
| White, G | 1 |
| Moreno, J | 1 |
| Huengsberg, M | 1 |
| Stevenson, M | 1 |
| Navarro, JF | 2 |
| Quereda, C | 4 |
| Gallego, N | 1 |
| Antela, A | 1 |
| Mora, C | 1 |
| Ortuno, J | 1 |
| Moreno, A | 1 |
| Desatnik, HR | 1 |
| Foster, RE | 2 |
| Yoshizumi, MO | 1 |
| Roca, JA | 1 |
| Lee, DA | 1 |
| Lee, G | 1 |
| Gomez, I | 1 |
| Enger, C | 3 |
| Forman, M | 3 |
| Bressler, N | 1 |
| Hoover, DR | 1 |
| Peng, Y | 1 |
| Saah, A | 1 |
| Semba, R | 1 |
| Detels, RR | 1 |
| Rinaldo, CR | 1 |
| Phair, JP | 1 |
| Wu, AW | 1 |
| Coleson, LC | 1 |
| Holbrook, J | 1 |
| Dodds, EM | 1 |
| Avery, RK | 1 |
| Prayson, RA | 1 |
| López-Cortés, LF | 1 |
| Pachón-Díaz, J | 1 |
| Flaherty, JF | 1 |
| Hardy, D | 1 |
| Conn, J | 1 |
| Colman, P | 1 |
| Brown, G | 1 |
| Street, A | 1 |
| Bate, K | 1 |
| Zaman, MM | 1 |
| Burney, S | 1 |
| Landman, D | 1 |
| Quale, JM | 1 |
| Patel, SS | 1 |
| Rutzen, AR | 1 |
| Marx, JL | 1 |
| Thach, AB | 1 |
| Chong, LP | 1 |
| Rao, NA | 1 |
| Nasir, MA | 1 |
| Jaffe, GJ | 1 |
| Drusano, GL | 1 |
| Jacobson, M | 1 |
| Polis, M | 1 |
| Lane, HC | 1 |
| Eaton, C | 1 |
| Martin-Munley, S | 1 |
| Sastry, SM | 1 |
| Epps, CH | 1 |
| Walton, RC | 2 |
| Rana, SN | 1 |
| Sanders, RJ | 1 |
| Luelmo, J | 1 |
| Sala, M | 1 |
| Sasal, M | 1 |
| Cervantes, M | 1 |
| Soriano, V | 1 |
| Mas, A | 1 |
| Bravo, R | 1 |
| Moreno, V | 1 |
| González-Lahoz, J | 1 |
| Segondy, M | 1 |
| Montes, B | 1 |
| Delmas, B | 1 |
| Leclercq, C | 1 |
| Janbon, F | 1 |
| Reynes, J | 1 |
| Carosi, G | 2 |
| Castelli, F | 2 |
| Lernestedt, JO | 1 |
| Antoniazzi, E | 1 |
| Breton, G | 1 |
| Crémieux, AC | 1 |
| Bright, DC | 1 |
| Hardy, WD | 1 |
| Whitcup, SM | 2 |
| Mueller, BU | 1 |
| Lewis, LL | 1 |
| Pizzo, PA | 1 |
| Mallolas, J | 1 |
| Gatell, JM | 1 |
| Gómez-Sirvent, JL | 1 |
| Buira, E | 1 |
| Zamora, L | 1 |
| Alecrim-Andrade, J | 1 |
| Adán, A | 1 |
| Morales, M | 1 |
| Miró, JM | 1 |
| Lonća, M | 1 |
| Guelar, A | 1 |
| Soriano, E | 1 |
| Moore, DA | 1 |
| Nelson, MR | 1 |
| Stalder, N | 1 |
| Sudre, P | 1 |
| Olmari, M | 1 |
| Opravil, M | 1 |
| Gabriel, V | 1 |
| Sansonetti, A | 1 |
| von Overbeck, J | 1 |
| Herbort, CP | 1 |
| Hirschel, B | 1 |
| Mueller, AJ | 1 |
| Hurwitz, S | 1 |
| Chuang, EL | 2 |
| Haidt, SJ | 1 |
| Kaplan, HJ | 1 |
| Tomasoni, L | 1 |
| Zeroli, C | 1 |
| Suter, F | 1 |
| Trespi, G | 1 |
| Hedman, A | 1 |
| Speyrer, MP | 1 |
| Katlama, C | 2 |
| Okamoto, T | 1 |
| Okada, M | 1 |
| Mori, A | 1 |
| Saheki, K | 1 |
| Takatsuka, H | 1 |
| Wada, H | 1 |
| Tamura, A | 1 |
| Fujimori, Y | 1 |
| Takemoto, Y | 1 |
| Kanamaru, A | 1 |
| Kakishita, E | 1 |
| Pérez-Blázquez, E | 1 |
| Traspas, R | 1 |
| Méndez Marín, I | 1 |
| Montero, M | 1 |
| Lalezari, JP | 2 |
| Usui, N | 1 |
| Usui, M | 1 |
| Guembel, HO | 1 |
| Hofmann, F | 1 |
| van Even, G | 1 |
| Makabe, R | 1 |
| Smith, CL | 1 |
| Pau, AK | 1 |
| Silverstein, BE | 1 |
| Smith, JH | 1 |
| Sykes, SO | 1 |
| Jones, MR | 1 |
| Schwartz, D | 1 |
| Cunningham, ET | 1 |
| Tural, C | 1 |
| Romeu, J | 1 |
| Sirera, G | 1 |
| Andreu, D | 1 |
| Conejero, M | 1 |
| Ruiz, S | 1 |
| Jou, A | 1 |
| Bonjoch, A | 1 |
| Ruiz, L | 1 |
| Arnó, A | 1 |
| Clotet, B | 1 |
| Ciulla, TA | 1 |
| Rutledge, BK | 1 |
| Morley, MG | 1 |
| Duker, JS | 1 |
| Schürmann, D | 1 |
| Bergmann, F | 1 |
| Grobusch, MP | 1 |
| Behnsch, M | 1 |
| Liekfeld, A | 1 |
| Althaus, C | 2 |
| Loeffler, KU | 1 |
| Schimkat, M | 1 |
| Hudde, T | 1 |
| Sundmacher, R | 1 |
| Park, SS | 1 |
| Girard, B | 1 |
| Font, RL | 1 |
| Hauw, JJ | 1 |
| Ries, E | 1 |
| Mühlbauer, B | 1 |
| Ruhswurm, I | 1 |
| Krepler, K | 1 |
| Derbolav, A | 1 |
| Svolba, G | 1 |
| Rieger, A | 1 |
| Wedrich, A | 1 |
| Marousek, G | 1 |
| Parenti, DM | 1 |
| Gordon, SM | 1 |
| LaVoy, AG | 1 |
| Ross, JG | 1 |
| Miner, RC | 2 |
| Drew, WL | 4 |
| Maurice-Estepa, L | 1 |
| Daudon, M | 1 |
| Jouanneau, C | 1 |
| Sazdovitch, V | 1 |
| Lacour, B | 1 |
| Beaufils, H | 1 |
| Goldfarb, DS | 1 |
| Coe, FL | 1 |
| Garcia, CR | 1 |
| Torriani, FJ | 1 |
| Barba, R | 1 |
| Gómez-Rodrigo, J | 1 |
| Marco, J | 1 |
| Espejo, M | 1 |
| Mena, D | 1 |
| Cherrington, JM | 1 |
| Fuller, MD | 1 |
| Lamy, PD | 1 |
| Miner, R | 1 |
| Nuessle, S | 1 |
| Zeichner, SL | 1 |
| Verbraak, FD | 1 |
| van den Horn, GJ | 1 |
| van der Meer, JT | 1 |
| Paydafar, D | 1 |
| ten Kate, FJ | 1 |
| Wertheim-van Dillen, PM | 1 |
| Kijlstra, A | 1 |
| Cochereau, I | 1 |
| Belayachi, N | 1 |
| Diraison, C | 1 |
| Matheron, S | 1 |
| Bouyer, I | 1 |
| Hoang-Xuan, T | 1 |
| Saimot, AG | 1 |
| Coulaud, JP | 1 |
| Fuchs, AV | 1 |
| Wolf, E | 1 |
| Scheider, A | 1 |
| Jäger, H | 1 |
| Kampik, A | 1 |
| Skiest, DJ | 2 |
| Cheng, L | 1 |
| Hostetler, KY | 1 |
| Gardner, MF | 1 |
| Avila, CP | 1 |
| Keefe, KS | 1 |
| Wiley, CA | 1 |
| Rabkin, CS | 1 |
| Testa, MA | 1 |
| Huang, J | 1 |
| Von Roenn, JH | 1 |
| Walmsley, S | 1 |
| Tseng, A | 1 |
| Hoy, J | 1 |
| Au Eong, KG | 1 |
| Beatty, S | 1 |
| Charles, SJ | 1 |
| Wutoh, AK | 1 |
| Hidalgo, J | 1 |
| Rhee, W | 1 |
| Bareta, J | 1 |
| Steidl, S | 1 |
| Labetoulle, M | 1 |
| Goujard, C | 1 |
| Frau, E | 1 |
| Rogier, H | 1 |
| Niessen, F | 1 |
| Furlan, V | 1 |
| Lantz, O | 1 |
| Lecointe, D | 1 |
| Delfraissy, JF | 1 |
| Offret, H | 1 |
| Hubbard, LD | 1 |
| Gilpin, AK | 1 |
| Meinert, C | 1 |
| Reshef, DS | 1 |
| Witte, T | 1 |
| Werwitzke, S | 1 |
| Schmidt, RE | 1 |
| Best, J | 1 |
| Kersten, A | 1 |
| Theisen, A | 1 |
| Gantke, B | 1 |
| Hoffman, VF | 1 |
| Crippa, F | 1 |
| Corey, L | 1 |
| Sale, G | 1 |
| Boeckh, M | 1 |
| Fine, HF | 1 |
| Smith, JA | 1 |
| Murante, BL | 1 |
| Robinson, MR | 2 |
| Velez, G | 1 |
| Roy, CE | 1 |
| Chan, CC | 1 |
| Blanchet, KD | 1 |
| Cheng, B | 1 |
| Woodward, J | 1 |
| Baker, R | 1 |
| Bowers, M | 1 |
| Smart, T | 1 |
| Palestine, AG | 1 |
| Spector, SA | 1 |
| Highleyman, L | 1 |
| Lee, TA | 1 |
| Sullivan, SD | 1 |
| Veenstra, DL | 1 |
| Ramsey, SD | 1 |
| Steger, PJ | 1 |
| Malinverni, R | 1 |
| Pleil, AM | 1 |
| Williamson, T | 1 |
| Ohta, H | 1 |
| Matsuda, Y | 1 |
| Tokimasa, S | 1 |
| Sawada, A | 1 |
| Kim, JY | 1 |
| Sashihara, J | 1 |
| Amo, K | 1 |
| Miyagawa, H | 1 |
| Tanaka-Taya, K | 1 |
| Yamamoto, S | 1 |
| Tano, Y | 1 |
| Aono, T | 1 |
| Yamanishi, K | 1 |
| Okada, S | 1 |
| Hara, J | 1 |
| Seo, SK | 1 |
| Regan, A | 1 |
| Cihlar, T | 1 |
| Lin, DC | 1 |
| Boulad, F | 1 |
| George, D | 1 |
| Prasad, VK | 1 |
| Kiehn, TE | 1 |
| Assi, AC | 1 |
| Lightman, S | 1 |
| Williams, IG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II, Double-Masked, Randomized, Placebo-Controlled Evaluation of Standard Therapy vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (MSL 109) in the Therapy of AIDS Patients With Cytomegalovirus (CMV) Retinitis[NCT00001061] | Phase 2 | 167 participants | Interventional | Completed | |||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| A Phase I Open-Labeled Study of Long Term Combined or Alternating Foscarnet/Ganciclovir Maintenance Therapy for AIDS Patients With CMV Retinitis After Ganciclovir Induction Therapy[NCT00000970] | Phase 1 | 30 participants | Interventional | Completed | |||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| Cytomegalovirus Retinitis Retreatment Trial[NCT00000134] | Phase 3 | 279 participants (Actual) | Interventional | 1992-12-31 | Completed | ||
| CMV Retinitis Retreatment Trial[NCT00000766] | Phase 2 | 300 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
To determine the best therapeutic regimen, using currently approved drugs, for treatment of relapsed cytomegalovirus (CMV) retinitis. (NCT00000134)
Timeframe: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial
| Intervention | participants (Number) |
|---|---|
| Intravenous Foscarnet | 88 |
| Intravenous Ganciclovir | 93 |
| Combination Therapy | 93 |
32 reviews available for foscarnet and Cytomegaloviral Retinitis
| Article | Year |
|---|---|
Management of Ganciclovir Resistant Cytomegalovirus Retinitis in a Solid Organ Transplant Recipient: A Review of Current Evidence and Treatment Approaches.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; | 2020 |
Cytomegalovirus Retinitis in Three Pediatric Cases with Acute Lymphoblastic Leukemia: Case Series and Review of the Literature.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Antiviral Agents; Child; Child, Presc | 2016 |
Progressive outer retinal necrosis presenting with isolated optic neuropathy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infection | 2004 |
Cytomegalovirus retinitis in patients with AIDS: current status.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganci | 1995 |
Local therapy for cytomegalovirus retinopathy.
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents, Local; Cytomegalovirus Retinitis; Dela | 1995 |
CMV retinitis treatment.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans | 1995 |
Promising new treatments for cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Implants | 1995 |
Current management of cytomegalovirus disease in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Therapy, Combination; Foscarn | 1994 |
Cytomegalovirus retinitis in persons with AIDS. Selecting therapy for a sight-threatening disease.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans; Mu | 1995 |
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1995 |
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.
Topics: Acidosis, Renal Tubular; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalov | 1996 |
A foveal-sparing pattern of cytomegalovirus retinitis in the acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1996 |
Current management of cytomegalovirus retinitis in AIDS update on ganciclovir and foscarnet for CMV infections.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cytomegalovirus Retinitis; Foscarn | 1996 |
[Treatment of cytomegalovirus infections in HIV infection].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus | 1996 |
Pharmacologic management of cytomegalovirus retinitis: review of current and future therapeutic modalities.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganci | 1997 |
Cytomegalovirus retinitis: diagnosis and status of systemic therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Diagnosis, Diffe | 1997 |
Management strategies for patients with cytomegalovirus retinitis.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalo | 1997 |
Therapeutic options for resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus | 1997 |
Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalo | 1997 |
Management of CMV retinitis in HIV infected patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytome | 1997 |
New treatment options for CMV retinitis in AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
[Cytomegalovirus retinitis].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retin | 1998 |
Local therapy for cytomegalovirus retinitis.
Topics: Administration, Topical; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; C | 1998 |
Cidofovir in the treatment of cytomegalovirus (CMV) retinitis.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Implants; Foscarnet; Ganciclo | 1998 |
Clinically resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; | 1995 |
Cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART).
Topics: Antiviral Agents; Biomarkers; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Diagnosis, Differentia | 1999 |
Comparative tolerability of therapies for cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; HIV Infections; Humans | 1999 |
Management of CMV infections in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1999 |
Cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Foscarnet; Ga | 1999 |
Therapeutic developments in cytomegalovirus retinitis.
Topics: Adenine; Antibodies, Monoclonal; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; D | 2000 |
Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis | 2001 |
Management of CMV disease in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 1999 |
28 trials available for foscarnet and Cytomegaloviral Retinitis
| Article | Year |
|---|---|
Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiretroviral Therapy, Highly | 2003 |
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Cytomegalovirus; Cyt | 2003 |
A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus re
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antiviral Agents; Cytomegalovi | 2004 |
Antiviral effects of foscarnet and ganciclovir therapy on human immunodeficiency virus p24 antigen in patients with AIDS and cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group in collaboration with AIDS Clinical Trials Group
Topics: AIDS-Related Opportunistic Infections; Antigen-Antibody Complex; Cytomegalovirus Retinitis; Female; | 1995 |
Foscarnet and ganciclovir pharmacokinetics during concomitant or alternating maintenance therapy for AIDS-related cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedul | 1995 |
Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1995 |
Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group.
Topics: Acute Kidney Injury; Adolescent; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retin | 1995 |
Foscarnet or ganciclovir for treatment of AIDS and CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Clinical Trials as Topic; Cytomegalovirus Retinitis; Foscarne | 1995 |
Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Resi | 1994 |
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Female; Foscarnet; Fundus O | 1994 |
Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; C | 1994 |
High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Female; Foscarnet; Humans; | 1994 |
Effect of foscarnet induction treatment on quantitation of human cytomegalovirus (HCMV) DNA in peripheral blood polymorphonuclear leukocytes and aqueous humor of AIDS patients with HCMV retinitis. The Italian Foscarnet Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retini | 1994 |
Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 1996 |
Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1995 |
Assessment of cytomegalovirus retinitis. Clinical evaluation vs centralized grading of fundus photographs. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1996 |
Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cross-Sectional Studies; Cytomegalov | 1996 |
Clinical vs photographic assessment of treatment of cytomegalovirus retinitis. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial Report 8. Studies of Ocular Complications of AIDS Research Group, AIDS Clinical Trials Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet | 1996 |
CMV retinitis: ganciclovir/monoclonal antibody.
Topics: Acquired Immunodeficiency Syndrome; Antibodies, Monoclonal; Antiviral Agents; Cytomegalovirus Retini | 1996 |
Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progression | 1996 |
Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients.
Topics: Analysis of Variance; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Disea | 1996 |
Convenient twice daily foscarnet in induction therapy of AIDS-associated cytomegalovirus retinitis. The Foscarnet Italian Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Admi | 1997 |
[Prophylaxis secondary to retinitis by CMV in patients with AIDS: the efficacy of an intermittent schedule of 3 days/week].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Admi | 1997 |
Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group
Topics: Adolescent; Adult; Age Factors; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphoc | 1997 |
Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Calcium; Cytomegalovirus | 1997 |
Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
Topics: Adult; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug | 1999 |
Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Studies of Ocular Complications of AIDS Research Group.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD8-Positive T-Lymphocytes; Cytomegalovirus | 2000 |
New trial for CMV retinitis.
Topics: Antibodies; Antiviral Agents; Combined Modality Therapy; Cytomegalovirus Retinitis; Foscarnet; Ganci | 1995 |
132 other studies available for foscarnet and Cytomegaloviral Retinitis
| Article | Year |
|---|---|
Efficacy of ganciclovir versus foscarnet in ganciclovir-resistant cytomegalovirus retinitis: A case report.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Humans; Male; Middle Aged; Trea | 2023 |
Acute Retinal Necrosis: Virological Features Using Quantitative Polymerase Chain Reaction, Therapeutic Management, and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Aqueous Humor; Cytomegalovirus Retinitis; DNA, Vir | 2019 |
Foscarnet calcium microcrystals as the intravitreal drug depot.
Topics: Animals; Antiviral Agents; Crystallization; Cytomegalovirus Retinitis; Foscarnet; Intravitreal Injec | 2017 |
Optic Nerve Swelling in a Patient With Cancer.
Topics: Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retinitis; Diagnosis, Differential | 2018 |
Cytomegalovirus retinitis in the absence of AIDS.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, V | 2013 |
Chronic retinal necrosis: cytomegalovirus necrotizing retinitis associated with panretinal vasculopathy in non-HIV patients.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Aqueous Humor; CD4 Lymphocyte Count; Chronic Disease; Cyt | 2013 |
Management of ganciclovir-resistant cytomegalovirus retinitis in HIV infection in the era of antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; HIV I | 2014 |
Intravitreal foscarnet for recurring CMV retinitis in a congenitally infected premature infant.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Female; Foscarnet; Ganciclovir; Gestational Age; Humans | 2014 |
Cytomegalovirus retinitis in HIV-negative patients: a practical management approach.
Topics: Adult; Aged; Antigens, Viral; Antiviral Agents; Child, Preschool; Cytomegalovirus; Cytomegalovirus R | 2015 |
Perivascular hypofluorescence in frosted branch angiitis.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; | 2015 |
Management of cytomegalovirus retinitis in HIV infection in the era of highly active antiretroviral therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Human | 2015 |
Dual Intravitreal Injections With Foscarnet and Ganciclovir for Ganciclovir-Resistant Recurrent Cytomegalovirus Retinitis in a Congenitally Infected Infant.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Viral; Drug Therapy, | 2016 |
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Topics: Alemtuzumab; Anemia, Refractory, with Excess of Blasts; Antibodies, Monoclonal; Antibodies, Monoclon | 2008 |
Cytomegalovirus retinitis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antibo | 2009 |
Mortality associated with resistant cytomegalovirus among patients with cytomegalovirus retinitis and AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agent | 2010 |
Sustained release of ganciclovir and foscarnet from biodegradable scleral plugs for the treatment of cytomegalovirus retinitis.
Topics: Animals; Biocompatible Materials; Chromatography, High Pressure Liquid; Conjunctiva; Cytomegalovirus | 2010 |
Fundus autofluorescence changes in cytomegalovirus retinitis.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cytomegalovirus Retinitis; Drug Implants; Femal | 2010 |
Polymerase chain reaction-based ganciclovir resistance testing of ocular fluids for cytomegalovirus retinitis.
Topics: Adult; Aged; Antiviral Agents; Aqueous Humor; Cytomegalovirus; Cytomegalovirus Retinitis; DNA-Direct | 2012 |
Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; DNA, Viral | 2012 |
Retinitis from cytomegalovirus during maintenance treatment for acute lymphoblastic leukemia.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Child; Cytomegalovirus Retinitis; Drug Therapy, C | 2012 |
Crystallization after intravitreous foscarnet injections.
Topics: Antiviral Agents; Crystallization; Cytomegalovirus Retinitis; Female; Foscarnet; Humans; Intravitrea | 2012 |
A possible coincidence of cytomegalovirus retinitis and intraocular lymphoma in a patient with systemic non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antiviral Agents; Cytomegalovirus; Cy | 2013 |
CMV retinitis after allogeneic bone marrow transplantation: a report of five cases.
Topics: Acyclovir; Adult; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus Retinitis; Female; | 2002 |
[Bilateral uveitis with definitive hypotony caused by systemic cidofovir].
Topics: AIDS-Related Opportunistic Infections; Cidofovir; Ciliary Body; Cytomegalovirus Retinitis; Cytosine; | 2003 |
[Acute retinal necrosis: clinical presentation, treatment, and prognosis in a series of 22 patients].
Topics: Acyclovir; Adolescent; Adult; Aged; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combi | 2004 |
Macular CMV retinitis: a case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Fatal Out | 2004 |
Intravitreal foscarnet for cytomegalovirus retinitis in patients with AIDS.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Fem | 2005 |
FDA notifications. FDA approves generic foscarnet sodium injection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Approval; F | 2005 |
Cytomegalovirus retinitis after fluocinolone acetonide (Retisert) implant.
Topics: Aged; Antiviral Agents; Behcet Syndrome; Cytomegalovirus Retinitis; Drug Implants; Fluocinolone Acet | 2007 |
Clinical features and outcomes of cytomegalovirus retinitis after transplantation.
Topics: Adult; Aged; Antiviral Agents; Cytomegalovirus Retinitis; Female; Foscarnet; Ganciclovir; Hematopoie | 2008 |
A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet-induced penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; H | 1995 |
Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Retinitis; Drug Therapy, Combination; Fem | 1995 |
Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Crystallization; Cytomegalovirus Retinitis; Foscarnet; | 1995 |
A sensitive and specific polymerase chain reaction-based assay for the diagnosis of cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Base Sequence; Cytomegalovirus; Cytomegalovirus Retinitis; DN | 1995 |
Cytomegalovirus encephalitis resistant to anti-cytomegalovirus therapy.
Topics: Bone Marrow Transplantation; Child, Preschool; Cytomegalovirus Infections; Cytomegalovirus Retinitis | 1995 |
Cytomegalovirus ventriculoencephalitis in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Autopsy; Brain; Cerebral Ventricles; Cerebrospinal Flu | 1995 |
Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; Cytomegalovirus Retinitis; Disease Pr | 1995 |
Intraocular sustained drug release devices.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Delayed-Action Preparations; Drug | 1995 |
Phosphonoformate for CMV retinitis in AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedule; Fosc | 1995 |
Resolution of oral hairy leukoplakia during treatment with foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Herpesviridae In | 1994 |
[Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1994 |
Efficacy of intravitreal foscarnet in a patient with AIDS.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Humans; Injections; Mal | 1994 |
In vitro anti-human cytomegalovirus activity of liposome-encapsulated foscarnet.
Topics: Cells, Cultured; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Carriers; Fibroblasts; Foscarnet; | 1994 |
Retinal detachment in patients with acquired immunodeficiency syndrome.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Follow-Up Studie | 1994 |
The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Cerebral Ventricles; Confusion; Cytomegalovirus | 1994 |
Combined daily therapy with intravenous ganciclovir and foscarnet for patients with recurrent cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Administration Schedul | 1994 |
Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Drug Resistance, Microbial; | 1993 |
Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus.
Topics: Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Microbial; Foscarnet; Ganciclovir; HIV | 1993 |
[Herpes zoster during foscarnet treatment in an AIDS patient].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1993 |
Long-term visual morbidity of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome.
Topics: Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Hum | 1993 |
Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis; Follow-Up Studies; Foscarnet; Ganc | 1993 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
Therapy for cytomegalovirus retinitis: still no silver lining.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1996 |
[Clinical manifestations and course of cytomegalovirus colitis in AIDS patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cohort Studies; Colitis; Colonoscopy | 1995 |
Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antibodies; Antiviral Agents; Cytomegalovirus Retinitis; Foscarn | 1994 |
Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Electrolytes; Foscarnet; Humans; Premedication; Prospec | 1995 |
Ganciclovir in cytomegalovirus retinitis.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Cytomegalovirus Retinitis; Drug Therapy, Combin | 1995 |
Renal tubular acidosis following treatment with foscarnet.
Topics: Acidosis, Renal Tubular; Adult; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; HIV Seroposi | 1995 |
Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Ret | 1996 |
Ocular iontophoretic supplementation of intravenous foscarnet therapy.
Topics: Animals; Antiviral Agents; Biological Availability; Chromatography, High Pressure Liquid; Cytomegalo | 1996 |
Cytomegalovirus retinitis and viral resistance. Prevalence of resistance at diagnosis, 1994. Cytomegalovirus Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Cytomegalovirus; Cytomega | 1996 |
Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lympho | 1996 |
Serous retinal detachments in a patient with clinically resistant cytomegalovirus retinitis.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus; Cytomega | 1996 |
New developments in the treatment of CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1996 |
[Current status of the management of cytomegalovirus retinitis in patients with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganciclo | 1996 |
Current and experimental therapeutic options for cytomegalovirus disease.
Topics: Administration, Oral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cyto | 1996 |
Current management of cytomegalovirus infection: treatment and prophylaxis.
Topics: Administration, Oral; Anti-Bacterial Agents; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Reti | 1996 |
Nephrogenic diabetes insipidus associated with foscarnet--a case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Rapid development of renal insufficiency with the simultaneous administration of amphotericin B and foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antiviral Agents; C | 1996 |
Cytomegalovirus papillitis in patients with acquired immune deficiency syndrome. Visual prognosis of patients treated with ganciclovir and/or foscarnet.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Infections; Cytomega | 1996 |
Cytomegalovirus retinitis associated with Hodgkin's disease.
Topics: Adult; Antiviral Agents; Biopsy; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, Viral; Fluorescein | 1996 |
Combined ganciclovir and foscarnet in pediatric cytomegalovirus retinitis.
Topics: Child, Preschool; Cytomegalovirus Retinitis; Drug Therapy, Combination; Enzyme Inhibitors; Female; F | 1996 |
[Genital ulcers from foscarnet: three cases].
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Genital Diseases, Male; Humans; Male; Ulcer | 1996 |
[Long term survival in an HIV-immunosuppressed patient treated with foscarnet].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegaloviru | 1996 |
Changes in HIV-1 RNA plasma level in patients treated with foscarnet.
Topics: Anti-HIV Agents; Cytomegalovirus Retinitis; Foscarnet; HIV Infections; HIV-1; Humans; RNA, Viral | 1997 |
Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Child; Child, Preschool; Cytomegalovirus Re | 1995 |
Central venous line infections in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1997 |
Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Swiss HIV Cohort Study Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Drug Therapy, Combination; | 1997 |
Re-evaluation of time to progression of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients clinically resistant to ganciclovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progress | 1997 |
Identification and treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retin | 1997 |
Successful treatment of severe cytomegalovirus retinitis with foscarnet and intraocular injection of ganciclovir in a myelosuppressed unrelated bone marrow transplant patient.
Topics: Adult; Antiviral Agents; Aqueous Humor; Bone Marrow Transplantation; Cytomegalovirus Retinitis; Fema | 1997 |
Intravitreal ganciclovir treatment in progressive outer retinal necrosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease P | 1997 |
Therapy with a combination of intravitreal foscarnet and intravenous ganciclovir in clinically resistant cytomegalovirus retinitis and patients with acquired immunodeficiency syndrome.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus R | 1996 |
New issues in the management of cytomegalovirus retinitis in AIDS patients.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1998 |
Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acetazolamide; Adult; AIDS-Related Opportunistic Infections; Anti-Inflammatory Agents, Non-Steroidal | 1998 |
Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cytomegalovirus | 1998 |
The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis | 1998 |
Lack of efficacy of cidofovir in treating AIDS-related cytomegalovirus retinitis after long-term treatment with ganciclovir.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Cidofovir; Cytomegalovirus Retinitis; | 1998 |
Prophylactic argon laser coagulation for rhegmatogenous retinal detachment in AIDS patients with cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Fundu | 1998 |
Immunohistochemical localization of ganciclovir in the human retina.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Delayed-A | 1998 |
Evaluation of cytomegalovirus retinitis management. Outcome of four years of cytomegalovirus therapy.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Body Fluids; CD4 Lymphocyte Count; Cytomega | 1998 |
Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine; Antiviral Agents; Cytomegalovirus; Cytomegalo | 1998 |
Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Resistance; Female; Fo | 1998 |
Identification of crystals in kidneys of AIDS patients treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1998 |
Foscarnet crystal deposition and renal failure.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Crystallization; Cytomegalovirus Retinitis; | 1998 |
Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Blood; Cidofovir; Cytomeg | 1998 |
Transient foscarnet-induced hypercalcaemia.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Female; F | 1998 |
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, | 1998 |
Foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Herpesviridae Infections; Humans | 1998 |
Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Biopsy; Cytomegalovirus Infections; | 1998 |
[Treatment of CMV retinitis with intravitreal foscarnet].
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progress | 1998 |
[Cytomegalovirus (CMV) retinitis in AIDS. Gancilovir implantation in comparison with systemic therapy].
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cyto | 1999 |
Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Delayed-Action Preparations; | 1999 |
Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; | 1999 |
Survival differences associated with treatment of cytomegalovirus retinitis in Maryland patients with AIDS, 1987-1994.
Topics: Adult; Age Factors; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cytome | 1999 |
Cidofovir: new preparation. Of help in CMV retinitis.
Topics: Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Retinitis; Cytosine; Foscarnet; Ganciclo | 1998 |
Ganciclovir resistance: a matter of time and titre.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; C | 2000 |
CMV complications in common variable immunodeficiency.
Topics: Adult; Antiviral Agents; Azathioprine; B-Lymphocytes; CD4-Positive T-Lymphocytes; CD8-Positive T-Lym | 2000 |
[Stopping secondary prevention in AIDS patients with inactive CMV retinitis treated with HAART (highly active antiretroviral therapy)].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cido | 2000 |
A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Re | 2000 |
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
Topics: Adult; Antiviral Agents; Chronic Disease; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cyt | 2001 |
Frosted branch angiitis in a child with HIV infection.
Topics: Antiviral Agents; Child; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Glucocorticoids; HIV Inf | 2001 |
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Ther | 2001 |
CMV retinitis: a clinical management update.
Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiviral Agents; Cidofovir; Clinical Protocols; | 1996 |
Support for new foscarnet indication for AIDS-related CMV retinitis is mixed.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Combination | 1997 |
Advances in the treatment of CMV.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials, Phase I as Topi | 1995 |
New developments in the delivery of ganciclovir for cytomegalovirus (CMV retinitis).
Topics: Administration, Oral; Cytomegalovirus Retinitis; Drug Costs; Drug Implants; Foscarnet; Ganciclovir; | 1995 |
New drug applications sought.
Topics: AIDS-Related Opportunistic Infections; Clarithromycin; Cytomegalovirus Retinitis; Drug Approval; Dru | 1995 |
Medicare may not reimburse for certain AIDS and cancer drugs.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Hu | 1995 |
Advances in treatment for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Cytomegalovirus Retiniti | 1995 |
Combination therapy improves CMV treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combi | 1996 |
Detecting CMV retinitis: know what to look for. Treatment is effective but not pleasant.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Cytomegalovirus Retiniti | 1996 |
CMV: the other virus.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retin | 1996 |
Intraocular therapy for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Dr | 1996 |
Spectrum and treatment of cytomegalovirus disease in persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Central Nervous System Diseases; Cy | 1996 |
Two-drug treatment effective against recurrent CMV retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1996 |
Foscavir receives new indication.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Co | 1997 |
Fomivirsen.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytome | 1998 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after stem cell transplantation: effective monitoring of CMV infection by quantitative analysis of CMV mRNA.
Topics: Adolescent; Antiviral Agents; Child; Cytomegalovirus; Cytomegalovirus Retinitis; Drug Resistance, Vi | 2001 |
Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance.
Topics: Antiviral Agents; Bone Marrow Transplantation; Cerebral Ventricles; Child; Cidofovir; Cytomegaloviru | 2001 |
Clinicopathologic reports, case reports, and small case series: cytomegalovirus retinitis in patients with Good syndrome.
Topics: Agammaglobulinemia; Aged; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; DNA, Viral; | 2002 |